Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bliss GVS PharmaBOM:506197 -0.87%59 PB Ratio is 4.61 as of Aug. 17, 2026, which is 205% above its 10-year median of 1.51. GuruFocus rates BOM:506197 with a GF Score™ of 59/100 and a GF Value™ of ₹170.07 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Bliss GVS Pharma ranks worse than 79.48% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-17), Bliss GVS Pharma's share price is ₹519.50. Bliss GVS Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was ₹112.76. Hence, Bliss GVS Pharma's PB Ratio of today is 4.61.
Warning Sign:
Bliss GVS Pharma Ltd stock PB Ratio (=4.65) is close to 10-year high of 4.65.
The historical rank and industry rank for Bliss GVS Pharma's PB Ratio or its related term are showing as below:
BOM:506197'
s PB Ratio Range Over the Past 10 Years
Min: 0.84 Med: 1.51 Max: 4.65
Current: 4.61
During the past 13 years, Bliss GVS Pharma's highest PB Ratio was 4.65. The lowest was 0.84. And the median was 1.51.
BOM:506197's PB Ratio is ranked worse than 79.48% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:506197: 4.61
During the past 12 months, Bliss GVS Pharma's average Book Value Per Share Growth Rate was 13.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bliss GVS Pharma was 29.30% per year. The lowest was -17.90% per year. And the median was 14.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bliss GVS Pharma PB Ratio Related Terms
Bliss GVS Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bliss GVS Pharma (BOM:506197) has a PB Ratio of 4.61 as of Aug. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bliss GVS Pharma and its competitors. This is 205% above median its historical median of 1.51. Over the past decade, Bliss GVS Pharma's PB Ratio has ranged from 0.84 to 4.65. According to the industry distribution chart, Bliss GVS Pharma ranks #732 out of 921 companies in the Drug Manufacturers industry, placing it in the top 79.5%.
Is Bliss GVS Pharma's PB Ratio too high?
Bliss GVS Pharma's current PB Ratio of 4.61 is 205% above median its 10-year median of 1.51. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 4.65. The Drug Manufacturers industry median PB Ratio is 1.97. Bliss GVS Pharma's value of 4.61 is 134% above this industry median. Based on the distribution chart, Bliss GVS Pharma ranks #732 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bliss GVS Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bliss GVS Pharma ranks #732 out of 921 companies for PB Ratio. This places Bliss GVS Pharma in the lower half of its industry. The industry median PB Ratio is 1.97. Bliss GVS Pharma's value of 4.61 is 134% above this benchmark. Historically, Bliss GVS Pharma's own PB Ratio has ranged from 0.84 to 4.65 over the past decade. While the company's 10-year median is 1.51 vs. the industry median of 1.97, Bliss GVS Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bliss GVS Pharma's current PB Ratio of 4.61 is 134% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bliss GVS Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bliss GVS Pharma's current PB Ratio is 4.61, which is 205% above median its own 10-year median of 1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹170.07, compared to a current price of ₹519.50 — trading 205.5% above its estimated fair value. The current PB Ratio is 4.61, which is 205% above median its 10-year median of 1.51 and 134% above the Drug Manufacturers industry median of 1.97. Bliss GVS Pharma's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current PB Ratio is 4.61 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹519.50 is trading 205.5% above its estimated GF Value™ of ₹170.07.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
PB Ratio: 4.61 (205% above median its 10-year median of 1.51)
GF Value™: ₹170.07 vs. price of ₹519.50 (205.5% above fair value)
Industry Position: 134% above the Drug Manufacturers median (#732 of 921)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
59GF Score
Get the complete analysis for BOM:506197
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
